




Bioscience Corporate Showcase 2011


Time	Company	Page
10:00 am	Makefield Therapeutics, Inc. Hybrid nanoparticle platform technology	2
10:20 am	Regeneron Pharmaceuticals, Inc. Integrated biopharmaceutical company (NASDAQ: REGN)	3
10:40 am	Visible Productions, Inc. 3D digital models of anatomical structures of the human body	4
11:00 am	Target Health Inc. Full-service CRO	5
11:20 am	ContraFect Corp. Infectious diseases	6
11:40 am	Vivaldi Biosciences Inc. Advanced flu vaccines	7
12:00-2:00	<i>Plenary luncheon program</i>	
2:00 pm	Signal Genetics LLC Cancer prognostics	8
2:20 pm	TechnoVax Inc. Vaccines for infectious diseases	9
2:40 pm	Aureon Biosciences, Inc. Cancer prognostics	10
3:00 pm	Argyle Therapeutics, Inc. Therapies for dermatological conditions	11
3:20 pm	Alkeus Pharmaceuticals, Inc. Ophthalmic conditions/macular degeneration	12
3:40 pm	Pfizer Worldwide Business Development Global biopharmaceuticals company (NYSE: PFE)	13
4:00 pm	10Biosystems LLC Life science software services	14
4:20 pm	Quartzy Laboratory management	15


 <p>Makefield Therapeutics Inc.</p>	<p>7 Larkspur Lane Newtown, PA 18940 www.makefieldtherapeutics.com</p> <p>Robert J. Towarnicki President & CEO rtowarnicki@makefieldtherapeutics.com</p>
<p>Company Background/ History</p>	<p>Makefield Therapeutics, Inc. is a privately held therapeutics company with two development programs addressed to very large market opportunities in anti-infectives and the treatment of erectile dysfunction, both based on an innovative nanoparticle drug delivery platform licensed from Albert Einstein College of Medicine of Yeshiva University. The proprietary nanoparticle technology will enable the Company to maintain a pipeline of novel therapeutics.</p>
<p>Products/ Technology & Markets</p>	<p>Makefield Therapeutics has two drug development programs addressed to multibillion dollar market opportunities: 1) A topically applied antimicrobial for the treatment of drug resistant skin and soft tissue infections that has demonstrated superior efficacy to current standards of care; and 2) a topical erectile dysfunction treatment targeting the 50% of men with ED for whom Viagra® and Cialis® don't work. The company expects to initiate clinical trials in the second half of 2012.</p>
<p>Management Team</p>	<p>Robert J. Towarnicki, President & CEO D. James Ballance, Ph.D., Vice President of R&D & CSO Joseph Johnson, Vice President of Translational Development</p>
<p>Recent Accomplishments or Milestones</p>	<p>Seed financing obtained from Ben Franklin Technology Partners of North Eastern Pennsylvania.</p> <p>Established a Laboratory at the Ben Franklin TechVentures Incubator at Lehigh University</p> <p>Completed a Regulatory Feasibility Study with RRI Group – Specialists in 505(b)(2) filings.</p>
<p>Forward Looking / Specific Partnering Needs</p>	<p>Makefield is seeking a \$3M Series A financing to advance its lead broad spectrum topical antimicrobial into Phase 1/2 clinical trial for the treatment of Impetigo colonized by drug resistant (MRSA) organisms. The company is also interested in partnering the enabling drug delivery technology in areas outside of its core focus in antimicrobial applications including: topical delivery of small molecule drugs; IV delivery of Nitric Oxide (NO); delivery of peptides, proteins and nucleic acids including siRNA; and other applications outside of pharmaceuticals (pesticides, fertilizers, food sciences, etc.</p>


		<p>777 Old Saw Mill River Road Tarrytown, NY 10591 Nasdaq: REGN www.regeneron.com</p> <p>Peter Dworkin, Vice President, Corporate Communications peter.dworkin@regeneron.com</p>
Company Background/ History	<p>Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. Founded in 1988 on the principle that strong science must be the foundation for developing important new medicines, Regeneron went public in 1991 and has grown to more than 1,500 employees in three locations: Tarrytown, NY (HQ), Rensselaer, NY (Industrial Operations and Product Supply), and Bridgewater, NJ (satellite office).</p>	
Products/ Technology & Markets	<p>Regeneron's first commercialized product, ARCALYST® (rilonacept) Injection for Subcutaneous Use, is an interleukin-1 inhibitor that is marketed for a rare genetic disease. Regeneron has 11 drug candidates in clinical development, including three fusion proteins developed with Regeneron's Trap technology that have been studied in Phase 3 trials for, respectively, the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Eight fully human monoclonal antibodies developed with Regeneron's Veloclmmune® antibody technology are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.</p>	
Management Team	<p>Leonard S. Schleifer, M.D., Ph.D. President and Chief Executive Officer</p> <p>George D. Yancopoulos, M.D., Ph.D. Executive Vice President, Chief Scientific Officer and President, Regeneron Research Laboratories</p> <p>Murray A. Goldberg Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary</p> <p>Peter Powchik, M.D. Senior Vice President,</p>	<p>Clinical Development</p> <p>Neil Stahl, Ph.D. Senior Vice President, Research and Developmental Sciences</p> <p>Robert J. Terifay Senior Vice President, Commercial</p> <p>Daniel Van Plew Senior Vice President and General Manager, Industrial Operations and Product Supply</p>
Recent Accomplishments or Milestones	<p>BLA for VEGF Trap-Eye for treatment of wet age-related macular degeneration (wet AMD) submitted in Feb. 2011. Positive Phase 3 trial results announced in Nov. 2010.</p> <p>Positive Phase 3 trial results of ARCALYST (rilonacept) for prevention of drug-induced gout flares announced in Feb. 2011 and June 2010.</p>	
Forward Looking / Specific Partnering Needs	<p>Regeneron's pharmaceutical collaborators are sanofi-aventis and Bayer Healthcare.</p> <p>Regeneron is hiring to fill a variety of open positions. For more information, go to www.regeneron.jobs/</p>	


	<p>213 Linden Street Suite 200 Fort Collins, CO 80524 www.visibleproductions.com</p> <p>Paul Baker pbaker@visiblep.com</p>
<p>Company Background/ History</p>	<p>Visible Productions, Inc. is a digital media company that develops and syndicates multimedia medical content. VP's combines compelling visuals with targeted healthcare content into persuasive education and communication programs. In the simplest of terms, VP takes medical and scientific information and makes it easy to understand for varying audiences through visualization. VP was formed in 1996 and has 23 employees based in Fort Collins, CO. It began by developing over 10,000 proprietary models of the human anatomy from the Visible Human data set created at the National Library of Medicine. With these models and the expansion of the internet, the Company has grown to be a leader in medical communication. It has a library of over 700 assets that it can license to distribution partners, such as MSN, Healthline, Yahoo!, etc.</p>
<p>Products/ Technology & Markets</p>	<p>VP develops and syndicates medical content targeted at patients, consumers and healthcare professionals. Its programs are unrivaled in their accuracy, aesthetics and impact with patients, consumers and healthcare professionals. Pharmaceutical and medical device manufacturers, health plans and insurers, health systems, and medical liability carriers ("Sponsors") pay for the development of the Programs. VP has developed a unique business model that allows VP to create and own the programs paid for by the Sponsors. This owned content becomes library assets that are syndicated to its partners. Our market is both the consumer of health information via the internet and the payors (health plans and employers) and providers (health professional and institutions) that need to educate patients and employees about their healthcare.</p>
<p>Management Team</p>	<p>Paul Baker, CEO Lewis Sadler, Chief Scientific Officer Joan McClusky, VP of Content Matt Faye, VP Production Rick Ellis, EVP Sales and Marketing Jason Gottlieb, VP New Business Development Dr. Stewart Greisman, Medical Director</p>
<p>Recent Accomplishments or Milestones</p>	<p>In Q2, 2011, the Company, in partnership with Healthline, will release a new product "BodyMaps". This interactive tool will allow users to visually search for medical content. BodyMaps uses all of the Company's anatomical models as a visual means of finding content. Healthline's search results provide the user with the most relevant content for the topic being searched. The Company also owns technology for mobile applications.</p>
<p>Forward Looking / Specific Partnering Needs</p>	<p>To expand its market presence the Company is looking for \$1.5 million of preferred equity. The proceeds will be used for sales and marketing and the development of content for its library that will allow it to expand into additional markets. The Company is also seeking content development and distribution partnerships.</p>


		261 Madison Avenue 24 th Floor New York, NY 10016 www.TargetHealth.com Warren M. Pearlson WPearlson@TargetHealth.com
Company Background/ History	Target Health Inc., established in 1993, is a privately held, New York City-based, full service eCRO with fulltime staff dedicated to all aspects of Regulatory Affairs, Chemistry, Manufacturing and Controls, Clinical Research, Biostatistics, Data Management, Medical Writing and Strategic Planning, with particular expertise and interest in strategic development of drugs/devices with unmet medical needs. Since 1993, we assisted in the approval of 28 products including 20 products marketed world-wide that used Target e*CRF [®] for data capture and data management for their pivotal trials.	
Products/ Technology & Markets	TARGET HEALTH is committed to bridging Internet-based technology with the drug and device development processes. Target Health has developed a full suite of eClinical Trial software including 1) Target e*CRF [®] (EDC plus randomization and batch edit checks), 2) Target e*CTMS [®] , 3) Target Document [®] , 4) Target Encoder [®] , 5) Target Newsletter [®] , 6) Target e*CTR [®] (electronic medical record for clinical trials).	
Management Team	Joyce Hays, CEO Dr. Jules Mitchel, President	
Recent Accomplishments or Milestones	Milestones include: 1) 20 EDC Regulatory approvals, 2) A major publication in the DIA Journal, 3) Release of Target e*Studio [®] which will allow for the configuration of Target e*CRF [®] applications by developers outside of Target Health. Our first contract has been signed by LSK Global Pharma Services out of Korea and 4) Initiation of at least 2 studies with Target e*CTR [®] (eClinical Trial Record), our direct data entry software, thus bypassing paper source records. Two INDs have already been cleared by FDA.	
Forward Looking / Specific Partnering Needs	Target Health has always taken a 2-tier approach to its growth. First is to develop drugs, biologics and devices for our clients. Second, is to develop software tools to optimize the product development processes. We are looking for partners who need assistance in product development as well as partners looking to globally distribute our software toolbox.	

	<p>469 7th Ave Third Floor New York, NY 10018 www.contrafect.com</p> <p>Barry Kappel, Ph.D., MBA VP, Business Development bkappel@contrafect.com</p>
<p>Company Background/ History</p>	<p>ContraFect Corporation, a New York-based biotechnology company, has assembled one of the most talented management and scientific teams in the industry. We are committed to developing technologies, treatments and products which target and kill the most virulent microorganisms – including gram-positive bacteria, such as Staphylococcus (MRSA) and viruses, such as Influenza.</p>
<p>Products/ Technology & Markets</p>	<p>ContraFect believes that treatment of drug-resistant pathogens requires new methods – those focusing on (a) combination therapy: attacking multiple targets on pathogens simultaneously using multiple Monoclonal Antibodies (Mabs) and Bactericidal Enzymes (Lysins), so that no single mutation or genetic reassortment can result in escape from therapy, or (b) single Mab or Lysin therapy to conserved targets: targeting specific parts of bacteria and viruses that do not mutate so that a single Mab can be used without worry of generating resistance.</p>
<p>Management Team</p>	<p>Robert Nowinski, Ph.D. – CEO, Chairman Isaac Blech – Director Sol Barer, Ph.D. – Director David Scheinberg, M.D., Ph.D. – Director Cary Sucoff – Director</p>
<p>Recent Accomplishments or Milestones</p>	<p>In 2010 ContraFect completed two financings totaling \$14.2M. With those proceeds ContraFect:</p> <ul style="list-style-type: none"> • Built its new laboratory and office facility in Yonkers, NY • Licensed a suite of 8 patents for Lysins (bactericidal enzymes) from The Rockefeller University from which it plans to create 12-14 distinct therapeutic products • Licensed a human phage display library and high-throughput robotics for antibody drug discovery
<p>Forward Looking / Specific Partnering Needs</p>	<p>In Q2 of 2011, ContraFect will:</p> <ul style="list-style-type: none"> • Launch its Series C financing • Initiate IND-enabling manufacturing of lead compound • Open up its new facility in Yonkers, NY <p>In Q3 of 2011, ContraFect will:</p> <ul style="list-style-type: none"> • Hold pre-IND meeting with the FDA regarding lead compound • Initiate IND-enabling toxicology program for lead compound


	<p>Bellevue Hospital Center 462 First Ave., Building A, 9th Fl. New York, NY 10016-9196 www.vivaldibiosciences.com</p> <p>Douglass B. Given, MD, PhD President & CEO doug.given@vivaldibiosciences.com</p>
<p>Company Background/ History</p>	<p>Vivaldi Biosciences Inc. was founded to develop and commercialize vaccines and therapeutics based on patented technologies of Drs. Peter Palese and Adolfo García-Sastre, licensed to the company by Mount Sinai School of Medicine (MSSM). Vivaldi is applying its proprietary NS1 biology platform to develop new-generation live attenuated influenza vaccines (LAIVs) and small-molecule antiviral drugs. The company completed a \$25 million Series A led by Bay City Capital and NGN Capital, with New York City Investment Fund and Alexandria Real Estate Equities. Vivaldi participates in NIH-funded grants worth over \$1M to the company, and has received city, state and federal tax credits totaling nearly \$1.5 million. Vivaldi's technology platform also benefits from significant and continuous NIH funding to MSSM over 10 years.</p>
<p>Products/ Technology & Markets</p>	<p>Seasonal influenza ("flu") is a serious viral disease and a significant public health problem. Worldwide, one billion cases of seasonal flu and up to 500,000 flu-related deaths occur annually. Each year, between 5% and 20% of the US population contracts flu, leading to 226,000 hospitalizations and 36,000 deaths. Elderly adults are the most vulnerable to flu and its serious complications, accounting for 90% of flu-related deaths. There is a compelling need and significant commercial opportunity for a more effective vaccine for the elderly. Standard flu vaccines are either less effective or not approved for adults over age 49. Vivaldi has developed a new-generation LAIV using proprietary genetic engineering techniques to alter the influenza NS1 gene and generate a vaccine optimized for safety and immunogenicity. NS1 is a key virulence factor produced by influenza in infected cells to evade the host immune response. Vivaldi's NS1-attenuated LAIV has a differentiated and potent mechanism of action. Administered as a single-dose nasal spray, it stimulates a strong interferon response in the nasal passages which suppresses replication of the virus, enhances immunogenicity, and elicits a potent protective and cross-protective immune response. Vivaldi has demonstrated high-yield production on egg substrate, with potential for significantly reduced production costs, and also is developing cell culture production. Vivaldi's antiviral program focuses on development of novel orally administered small-molecule therapeutics with activity against multiple influenza strains. Vivaldi has isolated and evaluated compounds that bind NS1 with high affinity to neutralize the virus's key virulence mechanism. This antiviral activity represents a distinct mode of action that is expected to circumvent the problem of resistance to the licensed antiviral drugs. Vivaldi is advancing compounds with highly potent, selective activity into lead optimization and preclinical development.</p>
<p>Management Team</p>	<p>Douglass Given, MD, PhD, MBA, President & CEO, Director David Liebowitz, MD, PhD, Chief Scientific Officer William Wick, MBA, Chief Financial Officer Brendan Rae, PhD, JD, Chief Business Officer</p>
<p>Recent Accomplishments</p>	<p>Selected LAIV candidate for clinical development Plan to file IND in mid 2011, and begin Phase 1 clinical program 2H11</p>
<p>Forward Looking / Specific Partnering Needs</p>	<p>Seeking additional funding through a Series B financing or HHS program. Encouraging clinical data may drive an opportunity for a pharma partnership or additional financing to support further development.</p>


 <p>SIGNALGENETICS™ MyPRS™ Myeloma Prognostic Risk Signature www.signalgenetics.com</p>	<p>667 Madison Ave, 14th Floor New York, NY 10065 www.signalgenetics.com</p> <p>Greg Richard grichard@signalgenetics.com</p>
<p>Company Background/ History</p>	<p>Signal Genetics was founded in 2010 through the acquisition of the intellectual property associated with 12 years of research in gene expression profiling for Multiple Myeloma at the University of Arkansas for Medical Sciences. In December, 2010 the Company launched its first commercial product, MyPRS, a proprietary prognostic test that stratifies Multiple Myeloma patients enabling physicians to choose a personalized approach to patient management. The Company has a CLIA lab located in Little Rock AR where the test is performed.</p>
<p>Products/ Technology & Markets</p>	<p>Currently the Company is focused on commercializing MyPRS (Myeloma Prognostic Risk Signature) among Hematologists/Oncologists in both the community and academic medical center settings. Signal has a national co-marketing Agreement with Caris Life Sciences to sell MyPRS to community-based Hematologists/Oncologists and is working to finalize a partnership with another commercial laboratory company to sell to the Academic Medical Center/Hospital market.</p>
<p>Management Team</p>	<p>Joe Hernandez, President and CEO Greg Richard, Exec. VP, Commercial Operations Tony Albino, Ph.D., Exec. VP Science and Technology</p>
<p>Recent Accomplishments or Milestones</p>	<p>The Company recently received Medicare coverage for MyPRS.</p>
<p>Forward Looking / Specific Partnering Needs</p>	<p>Signal Genetics has a rich pipeline of late stage prognostic signatures in Colon and Lung cancer and expects to launch a commercial product in both Colon and Lung cancer by the end of 2011.</p>


	<p>765 Old Saw Mill River Rd. Tarrytown, NY 10591 www.technovax.com Hector Munoz hmunoz@technovax.com</p>
<p>Company Background/ History</p>	<p>TechnoVax is a biotechnology company based in Westchester County (New York) that specializes in viral vaccine development. The company was founded in 2004 by Dr. Jose Galarza based on a license from Wyeth with co-exclusivity on certain indications and other proprietary technologies, the company has benefited from over \$5 million invested since 1996. We use our proprietary virus-like particle (VLP) technology platform to develop highly active, yet safe, vaccines. Successful pre-clinical milestones have been achieved with several pandemic influenza candidates (H5N1, H7N7, H1N1-1918) and we aim to initiate human clinical trials by year-end 2011.</p>
<p>Products/ Technology & Markets</p>	<p>TechnoVax has developed a novel way to produce highly immunogenic, non-infectious monovalent and polyvalent virus-like particle vaccines using a cell-based manufacturing system requiring no chemical inactivation. The technology is used to produce mass market vaccines for infectious diseases including influenza, respiratory syncytial virus (RSV), para-influenza virus (PIV) and other diseases such as Dengue, HIV and cancer. TechnoVax's novel polyvalent VLP vaccines are produced in a high yield single manufacturing step utilizing a new, low investment, continuous manufacturing process, reducing manufacturing time, steps and costs.</p>
<p>Management Team</p>	<p><u>Jose M. Galarza</u>, President and CEO. <u>George Martin</u>, Chief Technical Officer. <u>Hector Munoz</u>, Chief Financial & Corporate Development Officer.</p>
<p>Recent Accomplishments or Milestones</p>	<ul style="list-style-type: none"> • September 2009: TechnoVax won \$2.9 million in funding from the NIH (U.S. Department of Health and Human Services)to further support its vaccine programs. • 2010: Initiated discussions/negotiations with several 3rd parties for establishing potential <u>regional partnerships</u> in China, Japan, Middle-East, Mexico, Argentina, Scandinavia and Northern Europe. • December 2010: TechnoVax was awarded about \$0.5 million by the Department of Health and Human Services (HHS)through the IRS funded QTDP project. <p>Co-licensor has successfully achieved phase II clinical trials and was awarded a \$179 million contract by HHS BARDA to develop seasonal and pandemic influenza vaccines by using the same technology as TechnoVax's.</p>
<p>Forward Looking / Specific Partnering Needs</p>	<p><u>Plan & Strategy</u>: Actively seeking strategic partners in our target markets:</p> <ul style="list-style-type: none"> • At regional level; • Product centered; • Project oriented; <p>We plan to develop and commercialize safe and efficacious novel vaccines with the most time and cost-effective manufacturing technology in order to unlock significant commercial and competitive advantages.</p> <p><u>Target Market(s)</u>: TechnoVax' Addressable Market vaccine sales worldwide are projected to reach \$7 billion and to increase 12% per year.</p> <ul style="list-style-type: none"> • Regional and local markets with no current vaccine production capabilities seeking to take control of their national demand and supply. • Large and medium sized players, within the Pharmaceutical Industry, active or looking to enter the infectious diseases market.

	<p>28 Wells Avenue, 4th Fl Yonkers, NY 10701 www.aureon.com</p> <p>Jason Alter, PhD Jason.Alter@Aureon.com</p>
<p>Company Background/ History</p>	<p>Aureon Biosciences is a life science company specializing in risk assessment technology that enables patients and physicians to make personalized cancer treatment decisions. Prostate Px®+ utilizes biopsy tissue at diagnosis to help better assess “intermediate-risk” patients; while Post-Op Px™ is beneficial for those post-surgical patients that present with high-risk features.</p>
<p>Products/ Technology & Markets</p>	
<p>Recent Accomplishments or Milestones</p>	
<p>Forward Looking / Specific Partnering Needs</p>	

	<p>7 Deer Park Drive, Suite H Monmouth Junction, NJ 08852 www.ArgyleTherapeutics.com</p> <p>Dr. Braham Shroot, CEO T: 732.329.6344 bshroot@signumbio.com</p>
<p>Company Background/ History</p>	<p>Based on research conducted at Princeton University, Argyle Therapeutics Inc. is a biotechnology company developing small molecules derived from its lipid biomimetic platform which targets inflammatory skin diseases by controlling signal transduction.</p> <p>Argyle has a robust intellectual property portfolio protecting composition, methods of use, formulation, and manufacturing processes.</p>
<p>Products/ Technology & Markets</p>	<p>Argyle has identified an array of potent compounds for multiple dermal applications. The worldwide Rx market that is being targeted amounts to over \$14 billion and includes major inflammatory diseases such as: Acne, Atopic Dermatitis, Psoriasis, and Rosacea as well as the rapidly expanding area of prescription aesthetics.</p>
<p>Management Team</p>	<p>Dr. Braham Shroot – CEO Maxwell Stock – Founder & COO Anne VanLent – Financial Consultant Dr. Michael Voronkov, VP Medicinal Chemistry Dr. Eduardo Perez, VP of Dermatology R&D</p>
<p>Recent Accomplishments or Milestones</p>	<p>Term Sheets in hand for worldwide licensing arrangements</p> <p>February 17, 2011 – Spin-out from Signum Biosciences</p> <p>March 1, 2011 – Completed 2nd Licensing transaction with Rohto Pharma for commercial rights in Japan</p> <p>SBIR Grants – 4 Totaling over \$2.6M</p>
<p>Forward Looking / Specific Partnering Needs</p>	<p>Argyle is scheduled to file its first IND in May 2011 for Rosacea; targeting completion of Phase II by Q2 2013.</p> <p>Argyle also expects to file a second IND for Atopic Dermatitis in Q2 2012.</p>

	<p>Privately Held Operations in New York, Boston & Paris www.alkeus.com</p> <p>Leonide Saad, Ph.D. President & CEO Leonide@alkeus.com</p>
<p>Company Background/ History</p>	<p>Alkeus Pharmaceuticals, Inc., a Columbia University biopharmaceutical spin-out, is developing a portfolio of innovative treatments for serious ophthalmic conditions with high unmet medical needs. Its lead compound, ALK-001 is in phase 1 trials.</p>
<p>Products/ Technology & Markets</p>	<p>Alkeus' lead compound, ALK-001, is an improved form of vitamin A to be investigated as a potential treatment for dry-AMD, the leading cause of blindness in the western world (~10 million people in the U.S.) and Stargardt's disease, the most common form of juvenile blindness (30,000 people in the U.S., an orphan indication). Both of these chronic diseases lead to legal blindness and have no FDA approved treatments. The combined market size is estimated to be greater than \$10B.</p> <p>In animal models of macular degeneration, ALK-001 has shown significant reduction of the accumulation of toxic deposits in the retina, resulting in preservation of visual function at 12 months. No side effects or toxicity were observed.</p> <p>With a well understood mechanism of action, a validated target, and well known pharmacological properties, ALK-001 has a straight path through clinical trials and regulatory approval.</p>
<p>Management Team</p>	<ul style="list-style-type: none"> ▪ Leonide Saad, Ph.D., President and CEO ▪ Ilyas Washington, Ph.D., Michael Jaharis Assistant Professor at Columbia University, Advisory board member ▪ Jose Alain Sahel, M.D., Director of Paris Vision Institute, co-founder Fovea Pharmaceuticals, Advisory board member ▪ Koji Nakanishi, Ph.D., Centennial Professor at Columbia University, Advisory board member
<p>Recent Accomplishments or Milestones</p>	<p>Select 2010 achievements include:</p> <ul style="list-style-type: none"> ▪ Received FDA Orphan Designation (Stargardt's Disease) ▪ Obtained U.S. FDA IND approval for a phase 1 trial ▪ Near completion of GMP manufacturing of ALK-001 ▪ Secured validation and support from KOLs worldwide to perform clinical trials ▪ Published preclinical data in two scientific publications
<p>Forward Looking / Specific Partnering Needs</p>	<p>2011 Expected Developments:</p> <ul style="list-style-type: none"> ▪ Completion of phase 1 study ▪ Preparation of phase 2 trial data package and protocols ▪ Initiation of phase 2 trials ▪ Securing sufficient funding for phase 2 trials ▪ Collaborative partnership or licensing deal with large pharma ▪ Expansion of leadership team through new hires

	<p>430, E63 street, 3E New York, NY 10065 www.10biosystems.com</p> <p>Sebastian Jayaraj jayaraj@10biosystems.com</p>
<p>Company Background/ History</p>	<p>10BioSystems is a life science and healthcare-IT startup based in New York City, which provides scientific software products and consulting services. The company was founded in 2009 by biotechnology professionals with more than 20 years of work experience in academia, biotech industry and IT consulting. 10BioSystems works with biofuel & biotech companies, pharmaceuticals, research institutions and hospitals to provide innovative solutions for their unique informatics challenges.</p>
<p>Products/ Technology & Markets</p>	<p>10BioSystems offers enterprise software that addresses R&D needs from drug discovery to clinical data analysis. Our innovative products include online collaboration software for distributed scientific teams, LIMS for biology and chemistry, electronic lab notebook and clinical databases. All our products are web based, compliant and easily customizable.</p> <p>Our consulting practice is based on in-depth knowledge and experience in the biotech/pharma space. We couple our real world experiences with deep expertise in software development to offer high-value solutions. Practice areas include drug discovery and development, LIMS, mobile and cloud computing, bio and chem informatics, synthetic biology, hospital data management and custom software development.</p>
<p>Management Team</p>	<p>Sebastian Jayaraj, Co-founder and CEO Aakanksha Singhvi, Ph.D., Co-founder and COO</p>
<p>Recent Accomplishments or Milestones</p>	<ul style="list-style-type: none"> • Ranked second among 14 international companies in a World Health Organization competition to develop a scientific collaboration and innovation tracking system for researchers working on neglected diseases in Africa • Developed core facility genomics workflow LIMS for a large NYC based medical school • Implemented next-gen sequencing & metagenomics analysis system using cloud computing for NYC based research institute. • Deployed LIMS to track novel biologicals at a leading California biofuel company • Launched LabCentral – an online software service for scientific collaboration among distributed research teams
<p>Forward Looking / Specific Partnering Needs</p>	<p>10BioSystems aims to become the leading provider of online scientific software and services for life science research. By offering cloud based applications we plan on making high-quality software affordable to all scientists- whether in virtual biotechs or hospitals. Our consulting practice bolsters this approach by offering custom implementations and strategic solutions. We look forward to partnering with life science consortiums, healthcare companies and research communities to collaboratively develop next-generation scientific computing standards and applications.</p>

	<p>300, Fort Washington Ave, Suite 4D New York, NY 10032 www.quartzy.com</p> <p>Jayant E. Kulkarni, PhD Jayant@quartzy.com 855-QUARTZY(#701)</p>
<p>Company Background/ History</p>	<p>Quartzy is a privately held early-stage startup launched in 2009.</p>
<p>Products/ Technology & Markets</p>	<p>Quartzy aims to create a marketplace for life-science supplies and services (\$7B in the US) by developing and giving away for free online lab management and procurement software to the life-sciences industry. Our members are scientists in research labs in academia, pharmaceutical, and biotech companies. The business model is similar to Apple giving away itunes software for free in order to aggregate demand on their platform and charging record labels a transaction fee for songs sold on itunes.</p>
<p>Management Team</p>	<p>Jayant E. Kulkarni, PhD (CEO and cofounder) Gregg Hammerman, MBA (COO) Adam Regelmann, MD/PhD (Chief Scientific Officer and cofounder)</p>
<p>Recent Accomplishments or Milestones</p>	<p>Site launched Jan '09. Close to 4000 scientists from more than 200 institutions in the US, >50,000 logins, 160,000 inventory items and \$7M in orders tracked. Winner of the Olin Cup Business Plan Competition in 2010. Featured in the NY Times, Journal of Molecular Intervention and more.</p>
<p>Forward Looking / Specific Partnering Needs</p>	<p>Quartzy is looking for opportunities to license its intuitive online lab management and procurement platform to life-sciences labs in pharma and biotech companies.</p> <p>Quartzy is also aiming to raise a seed-round from qualified investors.</p>